NASDAQ:IBRX 29 November 2025

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159 million shares traded.

20 January 2026

NASDAQ:IBRX·Stock Market

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares.

18 January 2026

NASDAQ:IBRX·Pharmaceutical Industry·Stock Market

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares jumped sharply on Friday following a series of updates, including early sales figures for its approved bladder-cancer drug and new data from its development pipeline. The stock closed the day up 39.75% at $5.52 and later climbed to $6.04 in after-hours trading.

18 January 2026

NASDAQ:IBRX·Stock Market

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

Shares of ImmunityBio Inc surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of roughly 182 million shares.

17 January 2026

NASDAQ:IBRX·Stock Market

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete response at six months versus 57% on BCG alone and 84% versus 52% at nine months.

16 January 2026

Biotechnology·NASDAQ:IBRX·Pharmaceutical News·Stock Market

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20.

16 January 2026

Biotechnology·Health News·NASDAQ:IBRX·Stock Market

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia.

16 January 2026

NASDAQ:IBRX·Stock Market

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session.

13 January 2026

Biotechnology·NASDAQ:IBRX·Stock Market

ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

ImmunityBio shares were down 0.8% in premarket trading on Tuesday at $2.57, as of 5:00 a.m. ET. Around 13,000 shares had traded by that point, according to Public.com data. Premarket trading runs before the regular U.S. session opens at 9:30 a.m. ET and can be choppy.

13 January 2026

NASDAQ:IBRX·Stock Market

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

December 15, 2025 — ImmunityBio, Inc. is back on investors’ radar today as fresh coverage and new analysis dig into a major European regulatory milestone for its lead therapy ANKTIVA. The market’s obsession is simple: does this become the catalyst that turns ImmunityBio into a real commercial oncology story—or just the latest biotech pop before the harder work of reimbursement, uptake, and cash management begins?

15 December 2025

Financial Forecasts·NASDAQ:IBRX·Stock Market

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio, Inc. has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of bullish commentary across financial media.

29 November 2025

Biotechnology·Earnings Reports·NASDAQ:IBRX·Stock Market

NASDAQ:IBRX 29 November 2025 - 20 January 2026